Rab3ip: A Potential Drug Target Or Biomarker for PKC-Mediated Diseases

Target Name: RAB3IP

NCBI ID: G117177

RAB3IP

Rab3ip: A Potential Drug Target Or Biomarker for PKC-Mediated Diseases

Rab3ip (FLJ14660) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the Rab3 subfamily of the protein kinase C (PKC) family, which is involved in a wide range of cellular processes, including cell signaling, DNA damage repair, and metabolism.

One of the unique features of Rab3ip is its ability to interact with multiple protein substrates, including casein kinase (CK) 3, which is a protein that is involved in the regulation of protein kinase (PKC) activity. This interaction between Rab3ip and CK3 suggests that Rab3ip may be a drug target or biomarker for PKC-mediated diseases.

In addition to its interaction with CK3, Rab3ip has been shown to play a role in the regulation of several other cellular processes, including cell adhesion, migration, and survival. It is also involved in the regulation of inflammation and cellular signaling pathways that are important for the development and progression of a variety of diseases, including cancer.

The potential utility of Rab3ip as a drug target or biomarker is due to its involvement in multiple cellular processes that are important for the development and progression of disease. This makes it an attractive target for small molecule inhibitors, as well as antibodies that can specifically target Rab3ip.

In addition to its potential as a drug target or biomarker, Rab3ip is also a useful tool for studying the regulation of PKC activity. Researchers have used Rab3ip to study the effects of inhibitors on PKC activity, and have found that these inhibitors have a wide range of effects on cellular processes, including the regulation of protein synthesis, DNA damage repair, and cell survival.

Overall, Rab3ip is a protein that is involved in a wide range of cellular processes that are important for the development and progression of disease. Its interaction with multiple protein substrates, including CK3, suggests that it may be a drug target or biomarker for PKC-mediated diseases. Further research is needed to fully understand the role of Rab3ip in disease progression and the development of new therapeutic approaches.

Protein Name: RAB3A Interacting Protein

Functions: Guanine nucleotide exchange factor (GEF) which may activate RAB8A and RAB8B (PubMed:12221131, PubMed:26824392). Promotes the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form (PubMed:12221131, PubMed:26824392). Mediates the release of GDP from RAB8A and RAB8B but not from RAB3A or RAB5 (PubMed:20937701, PubMed:26824392). Modulates actin organization and promotes polarized transport of RAB8A-specific vesicles to the cell surface (PubMed:12221131). Together with RAB11A, RAB8A, the exocyst complex, PARD3, PRKCI, ANXA2, CDC42 and DNMBP promotes transcytosis of PODXL to the apical membrane initiation sites (AMIS), apical surface formation and lumenogenesis (PubMed:20890297)

The "RAB3IP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB3IP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets